DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference

DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference
  
 

MINNEAPOLIS, MINNESOTA--(Marketwired - Jun 10, 2014) - DiaMedica Inc. (TSX-VENTURE:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced it will be presenting a poster titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Recombinant Human Tissue Kallikrein-1 (DM199) in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus" at the American Diabetes Association's (ADA) 74th Scientific Sessions, being held on June 13-17 in San Francisco, California.

The poster has been assigned the presentation number 0977-P in category 01-D Clinical Therapeutics/New Technology - Non-Insulin Injectables. The poster is scheduled to be presented on Saturday, June 14th, 2014 from 11:30-1:30 pm.

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX-VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage product, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a novel monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.

The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

DiaMedica Inc.John SavageChief Financial [e-mail]